脂肪细胞因子与非酒精性脂肪肝病

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (4): 458-463.

脂肪细胞因子与非酒精性脂肪肝病

高娜¹, 严谨², 袁浩泳³, 欧阳冬生¹

¹中南大学临床药理研究所,长沙 410078,湖南;
²中南大学湘雅三医院,长沙 410013,湖南;
³中南大学基础医学院,长沙 410083,湖南

收稿日期:2010-02-25 修回日期:2010-03-12 发布日期:2020-09-17
通讯作者: 欧阳冬生,男,博士,副教授,硕导,主要从事临床药理学及中药现代化研究。Tel:0731-88927848 E-mail:ouyangyj@163.com
作者简介:高娜,女,硕士在读,主要从事脂肪肝方面的研究。Tel: 15874999284 E-mail: gao19820825na@163.com
基金资助:
湖南省科技计划资助项目(2007FG3035);国家大学生创新性实验计划资助项目(YB08105)

Adipocytokines and nonalcoholic fatty liver disease

GAO Na¹, YAN Jin², YUAN Hao-yong³, OUYANG Dong-sheng¹

¹Institute of Clinical Pharmacology ,Central South University,Changsha 410078, Hunan, China;
²The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China;
³School of Basic Medical Sciences, Central South University, Changsha 410083, Hunan, China

Received:2010-02-25 Revised:2010-03-12 Published:2020-09-17

摘要/Abstract

摘要： 非酒精性脂肪肝病是发病率仅次于病毒性肝炎的常见肝病,是隐原性肝硬化的主要危险因素之一。多种脂肪细胞因子参与了脂肪肝的病理过程。本文就脂联素、瘦素、抵抗素、内脏脂肪素、Apelin、肠凝集素、网膜素等7种脂肪细胞因子与非酒精性脂肪肝的关系研究进展作一综述。

关键词: 非酒精性脂肪肝, 脂肪细胞因子, 胰岛素抵抗

Abstract: Nonalcoholic fatty liver disease (NAFLD), one of the principal causes of cryptogenic cirrhosis, is the most common liver disease second to viral hepatitis. Adipocytokines contribute to fatty liver. We review the research progress of seven kinds of adipocytokines: adiponectin, lepin, resistin, visfatin, apelin, hepcidin and omentin, which may be associated with the non-alcoholic fatty liver disease.

Key words: Nonalcoholic fatty liver disease, Adipocytokine, Insulin resistance

中图分类号:

R575

高娜, 严谨, 袁浩泳, 欧阳冬生. 脂肪细胞因子与非酒精性脂肪肝病[J]. 中国临床药理学与治疗学, 2010, 15(4): 458-463.

GAO Na, YAN Jin, YUAN Hao-yong, OUYANG Dong-sheng. Adipocytokines and nonalcoholic fatty liver disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 458-463.

参考文献

[1] Kainuma M, Fujimoto M, Sekiya N, et al.Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis[J]. J Gastroenterol, 2006,41(10):971-980.
[2] Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity[J]. J Clinl Endocrinol Metab, 2005, 90(6) :3498-3504.
[3] Zhou MY, Xu AM,Tam PKH, et al. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury[J]. HEPATOLOGY, 2008, 48(4): 1087-1096.
[4] You M, Matsumoto M,Pacold CM,et al.The role of AMP-activated protein kinaseinthe action of ethanol in the liver[J]. Crastepoenterology,2004, 127(6): 1798-1808.
[5] Yamauchi T,Kamon J,Ito Y,et al.Cloning of adiponectin receptors that mediate antidiabetic metabolic effects[J]. Nature, 2003,423(6941):762-769.
[6] Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30[J]. J Clin Invest, 2001,108(13):1875-1881.
[7] Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis　in mice lacking adiponectin[J]. Gastroenterology, 2003, 125(6) :1796-1807.
[8] 于丹,马红.脂联素随原代HSC 活化表达的动态变化及其对原代HSC 表达MMP-13的影响[J].世界华人消化杂志, 2007,15(36):3793-3797.
[9] Hu ZW, Guo JW, Deng XL.Association of serum leptin and insulin resistance with nonalcoholic fatty liver disease[J].Nan Fang Yi Ke Da Xue Xue Bao, 2006, 26(6):853-855.
[10] Huang XD, Fan Y, Zhang H, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2008,14(18):2888-2893.
[11] Shivakumar C, Geoffrey, Linda F, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity[J]. Hepatology, 2002,36(2):403-409.
[12] Saxena NK, Ikeda K, Rockey DC,et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice[J]. Hepatology, 2002,35(4):762-771.
[13] Qamar A, Sheikh SZ, Masud A, et al. In vitro and in vivo protection of stellate cells from apoptosis by leptin[J]. Dig Dis Sci, 2006,51(10):1697-1705.
[14] Elinav E, Ali M, Bruck R,et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function[J]. Hepatology, 2009,49(1):278-286.
[15] Gove ME, Rhodes DH, Pini M, et al. Role of leptin receptor-induced STAT3 signaling in modulation of intestinal and hepatic inflammation in mice[J]. J Leukoc Biol, 2009,85(3):491-496.
[16] Steppan CM, Bailley ST, Bhat S, et al. The hormone resistin links obesity to diabetes[J]. Nature, 2001,409(6818):307.
[17] 饶绍琴,邓君,陈述,等.非酒精性脂肪肝患者血清抵抗素与胰岛素抵抗关系的探讨[J]. 中国实验诊断学, 2008,12(8):1024-1026.
[18] Muse ED, Obici S, Bhanot S, et al.Role of resistin in diet-induced hpatic insulin resistance[J]. J Clin Invest, 2004,114(2):232-239.
[19] Pagano C, Soardo G, Pilon C, et al.Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance[J]. J Clin Endocrinol Metab, 2006,91(3):1081-1086.
[20] 赵和平,杨文慧,段晓燕,等.动态观察非酒精性脂肪肝大鼠肝脏抵抗素的表达[J]. 国际内科学杂志, 2007,34(11):628-631.
[21] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005,307(5708):426-430.
[22] Atsunori F, Morihiro M, Masako N, et al. Visfatin: a protein secreted by visceral fat thatmimics the effects of insulin[J]. Science, 2005,307(5708):426-430.
[23] Li L, Yang G, Shi S, et al.The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo[J]. Cytokine, 2009,45(1):12-19.
[24] Murphy KG, Bloom SR. Are all fats created equa[J]? Nat Med, 2006,12(1):32-33.
[25] Johansson LM, Johansson LE, Ridderstrle M.The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects[J]. Metabolism, 2008,57(11):1558-1562.
[26] Aller R, de Luis DA, Izaola O, et al.Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease[J]. Dig Dis Sci, 2009,54(8):1772-1777.
[27] Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice[J]. Cell Metab, 2008,8(5):437-445.
[28] Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B, et al. Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats[J]. Br J Nutr, 2009,101(7):1059-1067.
[29] 魏丽,贾伟平,吴海娅,等.肥胖及2型糖尿病患者血清apelin水平及其相关因素分析[J]. 中华内分泌代谢杂志, 2007,23(2):130-133.
[30] Principe A, Melgar-Lesmes P, Fernández-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease[J]. Hepatology, 2008,48(4):1193-1201.
[31] Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH[J]. Gastroenterology, 2006,131(3):788-796.
[32] Barisani D, Pelucchi S, Mariani R, et al.J Hepatol. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload[J]. 2008,49(1):123-133.
[33] Hsiao TJ, Chen JC, Wang JD.Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients[J]. Int J Obes Relat Metab Disord, 2004,28(1):167-172.
[34] Mitsuyoshi H, Yasui K, Harano Y, et al. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease[J]. Hepatol Res, 2009,39(4):366-373.
[35] Wurm S, Neumeier M, Weigert J, et al. Plasma level s of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults[J]. Cardiovasc Diabetol Cardiovasc Diabetol, 2007,6:7.
[36] Kalra SP. Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions[J]. Peptides, 2008,29(1):127-138.